Rocket One Inc. Common Stock (RKTO) – Research Analysts’ Recent Ratings Updates

Rocket One Inc. Common Stock (NASDAQ: RKTO) has recently received a number of price target changes and ratings updates:

• 10/29/2026 – Rocket One Inc. Common Stock was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 10/25/2026 – Rocket One Inc. Common Stock was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 10/17/2026 – Rocket One Inc. Common Stock was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 10/14/2026 – Rocket One Inc. Common Stock was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 9/16/2026 – Rocket One Inc. Common Stock was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.